Michael Burry Called the 2008 Crash. Now He's Shorting Nvidia to Buy This Boring Healthcare Stock.

Michael Burry’s final disclosed position reportedly included put options on NVIDIA and Palantir, alongside a heavy 51% rotation into Molina Healthcare, after he later warned of an "AI Bubble." The filing signals a bearish stance toward leading AI names and a defensive shift into healthcare, but the article is largely a positioning update rather than a direct operational catalyst. Market impact is moderate and most relevant for sentiment in AI stocks and Burry-related trading interest.

Analysis

The bigger signal is not the directional bearishness on two crowded AI winners, but the capital rotation into a defensive cash-flow compounder at the same time. That combination often shows up late in a factor cycle: investors are willing to pay up for duration and narratives until vol rises, then the marginal seller moves into lower-beta healthcare where earnings visibility is higher and multiple compression is less violent. If that pattern holds, the next leg down in AI could be driven less by fundamentals than by position unwinds and dealer gamma flipping negative, which can accelerate declines over days to weeks.

NVDA is the more fragile of the two AI exposures because its equity story is tightly linked to capex momentum and sentiment around AI monetization timing. Any sign of customer digestion, export friction, or cloud capex moderation would matter more than headline demand, because the stock is priced for sustained perfection; that creates asymmetric downside if growth merely normalizes. PLTR is more idiosyncratic: its valuation already embeds multiple years of execution, so it can absorb slower growth better than NVDA, but it is still highly exposed to momentum funds and narrative crowding, making it vulnerable in a risk-off tape.

The healthcare rotation implies a second-order trade: if money is leaving high-beta software/semis for defensive managed care, the broader market is probably signaling a regime shift from “multiple expansion” to “earnings defense.” MOH stands out because it can benefit from rotation without needing a macro re-acceleration, but the trade is not purely duration-protective — reimbursement and medical cost inflation can still compress margins if utilization trends turn adverse. The contrarian view is that the AI selloff may be overdone if investors interpret one high-profile bearish hedge as proof of a bubble; in that case, the sharpest rebound would come from the names with the cleanest earnings revisions and the highest short interest squeeze potential, especially if QQQ stabilizes and vol compresses.

Key Decisions for Investors

• Trim or hedge NVDA into strength over the next 1-3 weeks; if the stock breaks below recent support, downside can accelerate 8-12% on dealer unwinds. Prefer put spreads over outright puts to cap theta if timing is uncertain.
• Maintain a tactical short PLTR versus a long basket of defensives; the stock is more vulnerable to de-rating than to estimate cuts, so a 1-2 month horizon with tight risk control is preferable. Use a call spread buyback as the stop if momentum reasserts.
• Initiate a pair trade: long MOH / short a basket of AI bellwethers (NVDA, PLTR) for a 4-8 week relative-value expression. The thesis is factor rotation, not company-specific collapse, so the target is mean reversion in valuation dispersion.
• For traders wanting convexity, buy NVDA 2-4 month put spreads on any bounce rather than chasing downside after a selloff. The risk/reward improves if implied volatility stays elevated but not explosive.
• If QQQ holds and AI leadership reclaims trend within 2 weeks, cover short exposure quickly; the main risk is a brief positioning flush that resets sentiment without changing fundamentals.